Posted by Michael Wonder on 21 May 2019
South Africa's Aspen sells Australian prescription portfolio to Mylan
20 May 2019 - Aspen Pharmacare has said that Mylan had exercised an option to buy the South African drug maker’s portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).
In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialised in Australia and New Zealand.
That deal included an option for Mylan to buy the portfolio.
